WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that Chelsea Clinton, the longest-serving member of its Board of Directors, having joined the Board in early 2017, will conclude her service as of October 31, 2025. During her over eight years of dedicated service, Ms. Clinton played a pivotal role in guiding Clover’s evolution from a privately held company serving 30,000 members to a publicly trade ...

Oct 31, 2025 11:00 AM Eastern Daylight Time TruBridge Announces Third Quarter 2025 Conference Call to Be Held Friday, November 7, 2025 Share MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and community healthcare organizations, today announced that it will release its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the market closes. The Company ...

投资策略 - 当前对科技股投资需保持纪律性 重点关注估值水平 [1] - 黄金作为投资组合的平衡资产 应继续持有 尽管年内已大幅上涨 但在零售投资者中配置仍不足 [8] 公司分析：Agyant Tech - 公司业务模式为分析设备与服务 设备用于化学、食品、水、癌细胞和半导体分析 客户包括医院、制药设施和研究实验室 [3] - 公司被视为医疗保健科技公司 历史数据显示在13个中期选举周期中有11个周期医疗保健板块表现超越市场 2026年为中期选举年 [4] - 公司年内至今涨幅仅约6%-7% 表现落后于市场 [6] - 中美贸易关系改善和政府停摆结束可能对公司业务产生积极影响 [5][7] 市场环境与汇率 - 美元本月迄今上涨约1.75% 美元走弱有助于盈利超预期 [9] - 2026年赤字问题可能对美元构成下行压力 [10] - 下半年关于关税合宪性的听证会可能对美元施加压力 [11] 盈利季节 - 市场因亚马逊和苹果等公司的强劲盈利而上涨 [9]

October 27, 2025 04:01 AM GMT Healthcare Technology | North America HLTH Conference 2025: AI takes center, left and right of stage This year marked an inflection in tangible AI use cases driving efficiencies and cost reductions. As healthcare costs rise prohibitively above the pace of inflation, challenges and opportunities arise. We highlight takeaways from booth tours, discussions with private companies and panels. AI adoption is accelerating with a wide range of use cases: | M Healthcare Technology North ...

股价表现 - 公司股价在财报发布后单日大幅上涨近14% [1] - 同期标普500指数下跌1% 凸显公司股价表现强劲 [1] 第三季度财务业绩 - 第三季度总收入达到3.11亿美元 同比增长10% [2] - 非GAAP净利润为2400万美元 合每股0.51美元 低于去年同期的2600万美元 [2] - 两项关键业绩指标均显著超越分析师平均预期 分析师此前预计收入低于2.96亿美元 非GAAP每股收益仅为0.36美元 [3] 业绩驱动因素 - 基础护理点连接设备持续推动收入增长 [3] - 连接设备和技术服务的增长也对收入提升有所贡献 [3] 业绩展望 - 管理层上调全年总收入指引至接近11.8亿美元至略低于11.9亿美元 [4] - 预计2025年调整后每股收益为1.63美元至1.73美元 [4]

Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 BillionTOKYO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MEDIROM MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), has completed a private placement of new shares to its President and CEO, Yoshio Uekusa, and Director, Ryo Saito. This transaction is part of the previously announced Series A ro ...

New whitepaper demonstrates how CA enables primary care teams in resource-constrained settings to prevent, detect, and manage chronic disease.SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released a whitepaper demonstrating how Counterpart Assistant (CA) technology supports value‑ba ...

BOWIE, Md.--(BUSINESS WIRE)--Inovalon Powers 70% of Medicare Advantage Enrollees in 4+ Star Plans, Continuing to Outperform National Averages in 2026 CMS Star Ratings . ...

公司业务与竞争格局 - Phreesia Inc 是一家医疗保健技术公司，提供患者登记和互动平台，旨在简化患者体验并改善医疗结果 [1] - 公司在竞争格局中面临包括 Health Catalyst、Veracyte、Accolade、Castle Biosciences 和 Personalis 在内的多个同行，各公司财务指标各异 [1] 资本回报效率分析 - Phreesia 的投资资本回报率为 0.52%，显著低于其 7.01% 的加权平均资本成本，表明公司当前产生的回报未能超过其资本成本 [2] - Phreesia 的 ROIC 与 WACC 比率为 0.074，进一步凸显了资本利用效率低下 [2] - Health Catalyst 的 ROIC 为负 16.99%，WACC 为 6.57%，ROIC 与 WACC 比率为负 2.59，在创造超过资本成本的回报方面表现比 Phreesia 更差 [3] - Veracyte 的 ROIC 为 0.99%，WACC 为 13.50%，ROIC 与 WACC 比率为 0.073，尽管比率略低于 Phreesia，但仍表明其回报不足以覆盖资本成本 [4] - Accolade、Castle Biosciences 和 Personalis 的 ROIC 均为负值，分别为负 31.79%、负 4.28% 和负 30.51%，其 ROIC 与 WACC 比率分别为负 2.91、负 0.48 和负 2.60，表明在创造超过资本成本的回报方面面临重大挑战 [5] 行业整体状况 - Phreesia 及其同行普遍面临资本回报挑战，ROIC 低于或显著低于 WACC 的情况在行业中常见 [6] - 在同行公司中，Veracyte 显示出最高的增长潜力，尽管其 ROIC 与 WACC 比率仅为 0.073 [6]

Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute HealthcareDETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its pathway to offer the first AI- ...